Options
比較脂肪乳劑對極低出生體重兒早產兒視網膜病變的影響及使用抗血管內皮生長因子的治療效果
Date Issued
2021
Author(s)
黃雅琪
Ya-Chi Huang
Advisor
Abstract
研究目的:早產兒視網膜病變(ROP),在極低出生體重的嬰兒是很常見的併發症,而這樣的視網膜病變又是造成孩童失明最常見的原因;因此如果可以即早注意到相關的危險因子,並且在剛出生後,全靜脈營養(TPN)給予含魚油成分的脂肪乳劑,預期可以有效地讓早產兒視網膜血管發育完成;而在嚴重的早產兒視網膜病變,目前主要使用玻璃體內注射抗血管新生因子(Anti-VEGF)治療,我們也進一步分析使用不同種藥物(Bevacizumab or Ranibizumab),在網膜病變痊癒的時間,以及患者1年之後的視力狀況進行研究。研究方法及資料:從 2008年1月至2019年1月間,我們隨機分配進入新生兒加護病房的及低出生體重早產兒,納入標準為出生體重<1500克或懷孕週數小於31週,他們至少連續7天接受了單一靜脈營養乳劑配方,並被診斷為ROP,以及後續持續追蹤直到視網膜血管發育完成。研究的患者依據使用不同的脂肪乳劑分成兩組進行分析,第1組(soybean oil based脂質乳劑,2008年至2014年)和第2組(fish oil based脂質乳劑,2015年至2019年)。嚴重程度的ROP則根據早產兒視網膜病變的早期治療,對患者進行玻璃體內注射Anti-VEGF 治療。視力狀況則是根據治療後追蹤一年,評估患者眼睛的屈光度及眼軸長。統計數據由IBM SPSS Statistics分析,p值<0.05被認為具有統計學意義。研究結果:研究中我們納入了278名患者,極低出生體重的患者其ROP發生率為73%,而嚴重的ROP發生率為35.2%。以回歸分析顯示,出生年齡和體重對ROP的發生率影響更甚。比較不同的脂肪乳劑對ROP的影響,發現fish oil based脂質乳劑可以減少嚴重ROP的發生率,而且也可以幫助網膜血管發育完成的時間較短(P <0.001)。Bevacizumab 和 Ranibizumab在ROP的治療中顯示出相似的有效性(P = 0.345)。使用Bevacizumab 和 Ranibizumab治療的ROP患者,其平均球面度和眼軸長度在1歲時無顯著差異,回歸分析進一步發現,不同的脂質乳劑對屈光和眼軸長沒有影響,但是ROP的程度越嚴重,造成之後發展成嚴重近視和散光的情形越明顯。結論與建議:使用fish oil based脂質乳劑對於減少嚴重ROP的發生率和促進視力發育密切相關。
Objective: Retinopathy of prematurity (ROP) remains one of the leading causes of childhood blindness worldwide. The third trimester is an important duration for brain and retina development, and long-chain polyunsaturated fatty acids are structural and functional components. This study aimed to evaluate the ROP in very low birth weight infants with different types of parenteral emulsions. We also compare the effects of different anti-vascular endothelial growth factor in the management of ROP.Methods and Materials: We included patients admitted to Changhua Christian Hospital from Jan. 2008 to Dec. 2019. The inclusion criteria were infants who weighed below1500 g and had a gestational age below 31 weeks, received a single parenteral lipid emulsion formula, were diagnosed with any ROP stage, and were followed up until full retinal vascularization. Enrolled patients were randomized into group 1 (soybean-based lipid emulsion) or group 2 (fish oil-based lipid emulsion). The patients were treated by intravitreal injection with ranibizumab (IVR) or bevacizumab (IVB), as determined by the Early Treatment for Retinopathy of Prematurity. The cycloplegic refraction at 1 year of age was assessed using an autorefractometer.Results: We included 278 patients in this study. The ROP incidence in very low birth weight infants was 73%. Compared to soybean-based lipid emulsions, fish oil-based lipid emulsions were associated with a lower incidence of severe ROP and a lower regression time required to achieve a complete retinal vascularization. Bevacizumab and ranibizumab showed similar effectiveness in ROP treatment. Additional analyses revealed that patients with more severe ROP had worse myopia and astigmatism.Conclusions and Suggestion: This study demonstrated that fish oil-based lipid emulsions strongly associated with decreased ROP incidence and adequately promoted visual development.
Subjects
早產兒視網膜病變
魚油
靜脈營養
抗血管內皮因子
屈光
Retinopathy of prematurity
fish oil
parenteral nutrition
anti-vascular endothelial growth factor
refraction
Type
thesis
File(s)
No Thumbnail Available
Name
109CSMU5534036-001.zip
Size
489.31 KB
Format
Unknown
Checksum
(MD5):09476dd72fc33d811884e7b827f053da